Description

I help executive teams in pharma and biotech scale their organizations and deliver enterprise transformation—turning strategic ambition into disciplined execution. With 16+ years across argenx, UCB, Baxter and management consulting, I partner with CEOs and senior leaders to translate corporate vision into a clear strategy, roadmap, and practical execution engine (governance, portfolio prioritization, partners, cadence, and metrics) that delivers measurable outcomes in regulated environments.

My focus is on designing and delivering scaling strategies and enterprise transformation programs—redesigning operating models and workflows to support rapid growth, accelerate clinical development, improve decision speed and quality, enhance patient and HCP experience, and unlock productivity through data, automation and AI.

What I typically help leaders deliver

Strategy → Execution: Translate corporate vision into a strategic blueprint, prioritized roadmap, and sequenced initiative portfolio.
Scaling & Enterprise Transformation: Design and deliver transformation programs enabling growth without linear headcount increases.
AI-Enabled Transformation: Identify high-value AI use cases, establish delivery capabilities (e.g., AI CoE), and embed responsible adoption.
Operating Model & Execution Engine: Build teams, partner ecosystems, governance, and operating cadence required for execution at scale.
Portfolio & Investment Discipline: Scenario planning, prioritization frameworks, and stop/hold/go decisions aligned to strategic value.
Future-of-Work Productivity: Redesign workflows and ways of working to unlock enterprise productivity and scalability.
Executive Decision Support: Prepare ExCom and board narratives

What differentiates me is the combination of enterprise strategy, scaling execution, and deep understanding of the end-to-end drug development value chain

Domaines d’expertise

Langues

Anglais
Bilingue ou natif

Préférences en matière de lieu de travail

Accepte de travailler sur site

Leuven (jusqu’à 50 km), Brussels (jusqu’à 50 km)

argenx, Global Biotech Company (Rare Diseases)
Sr Director : R& D a n d Enterprise Transformation - AI/Data e n a b l e d
septembre 2021 - Aujourd'hui (4 ans et 9 mois)
• • Set strategic intent: Partnered with senior leaders to position transformation as a long-term enterprise priority focused on patient impact, development speed, scalability, and faster decisions.
• • Defined the portfolio: Identified the highest-impact themes, workflows and built a sequenced transformation portfolio tied to measurable outcomes.
• • Delivered pilots → scale: Led targeted workflow redesign pilots with SMEs, delivering shorter cycle times and effort; scaling successful pilots enterprise-wide.
• • Enabled scale and transformation without linear headcount: Supported scaling towards, from 10k→50k patients, 2→10 labeled indications, 1→5 Phase III assets.
◦ o Cut certain decision cycles from months to days, shortened development timelines by several months, and improved dossier productivity up to 30% via AI-enabled disease assessment, intelligence led pipeline decisions, data optimized trial design, patient engagement, and accelerated authoring.
◦ o Improved patient/HCP experience through insight-driven engagement with ~100% interaction capture and reuse as actionable intelligence.
◦ o Increased transversal productivity by >10% across ~3,000 people; strengthened inspection readiness and predictive supply capabilities.
• • Built the execution engine: Established a repeatable ExCom / Senior leaders cadence (prioritization, metrics, accountability) across transformation portfolio.
• • Built the operating ecosystem: Created and led an end-to-end delivery ecosystem from zero (internal teams + expert networks + CROs/CMOs + consultancies + tech partners), including cross-functional
• • Embedded adoption: Worked with change leaders to hardwire new ways of working into day-to-day workflows and leadership routines.
UCB Pharma, Global
Director : Epilepsy Franchise Head Strategy & Operations
janvier 2019 - janvier 2021 (2 ans)
• • Shaped "One Integrated Epilepsy Franchise", aligning long-term R&D and commercial ambition with disciplined portfolio and investment decisions across functions and regions.
◦ o Led development of a 10-year long-range plan and 3-year operating plans across R&D, Medical, Market Access, and Commercial for US, EU, Japan, and China.
◦ o Drove pipeline prioritisation and capital allocation, concentrating investment on high-potential assets while terminating or deprioritizing lower-value lifecycle programs - i.e. 2 lifecycle mgt programs stopped, ~25% resource reallocated
◦ o Addressed portfolio white space by orchestrating M&A assessments with BD and Corporate Strategy and leading end-to-end post-acquisition integration – i.e. 4 months for end-to-end integration.
• • Prepared and led Executive Committee and Board reviews, translating complex trade-offs, risks, and scenarios into decision-ready recommendations for endorsement.
• • Designed and implemented lean operating framework for the integrated epilepsy franchise, strengthening execution cadence and cross-functional alignment.
UCB Pharma, Global Biopharmaceutical Company
Associate Director - Global Program Leader – Early & Late Stage
janvier 2016 - janvier 2018 (2 ans)
• • Accelerated development and launch readiness for assigned assets, ensuring cross-functional alignment and execution discipline.
• • Integrated asset strategy into integrated development & launch plans, embedding scenario analysis, risk/opportunity trade-offs, and dependency mapping to inform senior decision-making.